CD274 and non-small cell lung carcinoma: After the use of other immunotherapies, like the anti-PD1 antibody pembrolizumab, the 5-year overall survival rate for first-line NSCLC patients (regardless of PD-L1 expression) ranges from 18–20% [31,32,33,34], which compares positively with the racotumomab data obtained in the real-world conditions.